Answers are grounded in this paper and cite their sources.
, bifidobacteria, and commensal clostridia. Microbiome data showed favorable differentiation compared to other CDI therapeutics. These results support further development of CRS3123 as an oral agent for the treatment of CDI. (This study has been registered at Clinicaltrials.gov under identifier NCT02106338.).
No takes yet. Share an insight, caveat, or question.
Lomeli et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: